Compare Adaptive Biotechnologies Corp (ADPT) vs Centene Corp (CNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Centene Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Centene Corp trades at $65.44 (market cap $32.05B). The key difference: Centene Corp is far larger — about 7.9× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | CNC | |
|---|---|---|
Market Cap | $4.04B | $32.05B |
Sector | Health | Health |
52-Week High | $25.45 | $68.72 |
52-Week Low | $12.30 | $26.17 |
Enterprise Value | $4.10B | $21.10B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
